bluebird bio, Inc. (BLUE) Earns “Hold” Rating from Jefferies Group LLC

Jefferies Group LLC reaffirmed their hold rating on shares of bluebird bio, Inc. (NASDAQ:BLUE) in a research report released on Friday, November 3rd. They currently have a $130.00 target price on the biotechnology company’s stock. Jefferies Group also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.71) EPS, FY2017 earnings at ($6.85) EPS, FY2018 earnings at ($7.26) EPS, FY2019 earnings at ($7.01) EPS, FY2020 earnings at ($4.19) EPS and FY2021 earnings at $4.38 EPS.

Several other equities research analysts have also recently commented on BLUE. Sanford C. Bernstein initiated coverage on shares of bluebird bio in a research report on Thursday, July 27th. They issued a market perform rating and a $109.00 price target on the stock. Cantor Fitzgerald reissued a sell rating and issued a $39.00 price target on shares of bluebird bio in a research note on Monday, July 24th. BMO Capital Markets reissued a buy rating and issued a $108.00 price target on shares of bluebird bio in a research note on Friday, August 4th. Evercore ISI began coverage on bluebird bio in a research note on Wednesday, August 16th. They set an in-line rating and a $102.00 target price on the stock. Finally, BidaskClub raised bluebird bio from a sell rating to a hold rating in a research note on Wednesday, August 9th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have issued a buy rating to the company. The company has a consensus rating of Buy and an average target price of $131.05.

bluebird bio (BLUE) traded up $5.35 during trading on Friday, reaching $162.25. 462,588 shares of the company’s stock were exchanged, compared to its average volume of 842,925. bluebird bio has a 1 year low of $56.80 and a 1 year high of $164.80.

bluebird bio (NASDAQ:BLUE) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The company had revenue of $7.71 million during the quarter, compared to the consensus estimate of $8.47 million. During the same quarter in the previous year, the business posted ($2.07) earnings per share. The business’s quarterly revenue was up 397.4% compared to the same quarter last year. equities analysts forecast that bluebird bio will post -6.68 EPS for the current year.

TRADEMARK VIOLATION WARNING: “bluebird bio, Inc. (BLUE) Earns “Hold” Rating from Jefferies Group LLC” was published by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/bluebird-bio-inc-blue-stock-rating-reaffirmed-by-jefferies-group-llc/1757197.html.

In other bluebird bio news, insider Jeffrey T. Walsh sold 1,250 shares of the stock in a transaction dated Monday, August 28th. The stock was sold at an average price of $107.06, for a total value of $133,825.00. Following the completion of the sale, the insider now directly owns 28,555 shares in the company, valued at $3,057,098.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Daniel Lynch sold 500 shares of the stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $120.00, for a total value of $60,000.00. Following the completion of the sale, the director now owns 3,300 shares of the company’s stock, valued at $396,000. The disclosure for this sale can be found here. Insiders have sold 193,168 shares of company stock worth $25,558,003 in the last ninety days. 3.90% of the stock is currently owned by insiders.

Several large investors have recently bought and sold shares of BLUE. Parametric Portfolio Associates LLC grew its holdings in shares of bluebird bio by 11.5% during the first quarter. Parametric Portfolio Associates LLC now owns 22,743 shares of the biotechnology company’s stock worth $2,067,000 after buying an additional 2,338 shares in the last quarter. Legal & General Group Plc grew its stake in bluebird bio by 2.6% in the first quarter. Legal & General Group Plc now owns 13,944 shares of the biotechnology company’s stock valued at $1,272,000 after purchasing an additional 357 shares in the last quarter. Vanguard Group Inc. grew its stake in bluebird bio by 4.6% in the first quarter. Vanguard Group Inc. now owns 3,215,246 shares of the biotechnology company’s stock valued at $292,266,000 after purchasing an additional 141,293 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in bluebird bio by 24.5% in the first quarter. Dimensional Fund Advisors LP now owns 84,961 shares of the biotechnology company’s stock valued at $7,723,000 after purchasing an additional 16,741 shares in the last quarter. Finally, BlackRock Inc. grew its stake in bluebird bio by 44,948.0% in the first quarter. BlackRock Inc. now owns 3,182,188 shares of the biotechnology company’s stock valued at $289,259,000 after purchasing an additional 3,175,124 shares in the last quarter.

bluebird bio Company Profile

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
Seattle Mariners Start Offseason With a Bang: Three Trades Over Four Days
MLB Commissioner: New Rule for Pace-of-Play in 2018
MLB Commissioner: New Rule for Pace-of-Play in 2018
Alex Cobb Could Be Good Fit for Cubs
Alex Cobb Could Be Good Fit for Cubs
Joey Votto Is One of Baseball’s Best Hitters
Joey Votto Is One of Baseball’s Best Hitters
Hunter Pence May Become Part-Time Player
Hunter Pence May Become Part-Time Player
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts
Perfect 300 Bowled by Red Sox Right Fielder Mookie Betts


Leave a Reply

 
© 2006-2017 BBNS.